Home progressionfree
 

Keywords :   


Tag: progressionfree

Mercks KEYTRUDA (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer

2016-06-16 12:45:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced cell treatment compared

 

Zydelig in Combination With Ofatumumab Improves Progression-Free...

2015-05-31 19:33:26| Biotech - Topix.net

Phase 3 Study Results Showing 73 Percent Reduction versus Ofatumumab Alone in Risk of Disease Progression or Death to be Presented at American Society of Clinical Oncology Annual Meeting -- CHICAGO-- -- Gilead Sciences, Inc. today announced results from the Phase 3 clinical Study 119 of an investigational use of ZydeligA in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukemia . In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab compared to ofatumumab alone = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001).

Tags: combination improves progressionfree ofatumumab

 
 

Amgen says Kyprolis doubles progression-free survival vs Velcade

2015-03-02 04:09:37| Biotech - Topix.net

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

Tags: survival doubles amgen progressionfree survival

 

Sites : [1]